DANIELS RONALD J
SEC Form 4 insider trading activity
DANIELS RONALD J has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.
On the most recent filing, DANIELS RONALD J is listed as Director at BridgeBio Pharma, Inc. Inside the rolling window, DANIELS RONALD J reported no open-market purchases and 1 open-market sale totaling $3.9M in BBIO.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has DANIELS RONALD J made?
DANIELS RONALD J has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does DANIELS RONALD J trade?
DANIELS RONALD J has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was DANIELS RONALD J's most recent SEC Form 4 filing?
DANIELS RONALD J's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.
What is DANIELS RONALD J's total buy and sell value in the current window?
Inside the rolling retention window, DANIELS RONALD J bought $0 and sold $3.9M based on SEC Form 4 filings.
What was DANIELS RONALD J's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 61,031 BBIO shares on 2025-11-06, worth $3.9M, per SEC Form 4 filings.